This is the most important safety post you will read about modafinil. Stevens-Johnson Syndrome (SJS) is a rare but potentially life-threatening reaction. Every modafinil user needs to know about it.
How rare is it? SJS from modafinil is extremely rare — estimated at fewer than 5 cases per million users. It is included in the FDA label and warrants awareness, not panic.
What to watch for:
- Any skin rash appearing within the first 5 weeks of starting modafinil (highest risk period)
- Rash accompanied by fever, mouth sores, or eye inflammation — these suggest a more serious reaction
- Blistering or peeling skin — stop immediately and seek emergency care
The rule: Any unexplained rash in the first 5 weeks of modafinil use = stop the drug and consult a doctor the same day. Most rashes will be benign. But with SJS, early cessation is the difference between a minor event and a serious one.
What is NOT SJS: Dry skin, existing eczema flares, or minor irritation unrelated to drug onset timeline are likely unrelated. But when in doubt, stop and check.
Pinned/sticky this kind of post. This is exactly the type of safety information every modafinil forum needs prominently displayed. The risk is tiny but the consequence of ignoring it is severe.
I developed a mild rash after 3 weeks on modafinil. Stopped immediately, saw my GP the next day. It was contact dermatitis from a new soap — not SJS, not modafinil-related. But the protocol was correct: stop, check, confirm.
Is there any genetic test that can predict SJS risk? I know some are being developed for other high-risk drugs like carbamazepine.
For modafinil specifically there is no validated pharmacogenomic test for SJS prediction currently in clinical use. For certain other drugs (abacavir, carbamazepine) HLA typing is used, but the specific HLA associations for modafinil SJS are not definitively established.
Would it be possible for a mod to add this to the sidebar or wiki? This seems like essential reading for anyone starting modafinil.
The first 5 weeks being the highest risk window is worth repeating. Once you have been on it for 2+ months without any reaction, the residual SJS risk is negligible.
To add some context: SJS risk is not unique to modafinil. It is associated with many common drugs including ibuprofen, amoxicillin, and some anticonvulsants. The principle of watching for early rash is good general drug safety practice.
Thank you for writing this up clearly without inducing panic. The “rare but real” framing with concrete action steps is exactly right.